Iterum Therapeutics announces U.S. commercial launch of ORLYNVAH

Iterum Therapeutics (ITRM) announced the U.S. commercial launch of ORLYNVAH oral tablets. The Food and Drug Administration approved ORLYNVAH for adult women with uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options in October 2024. ORLYNVAH is the first oral penem antibiotic commercially available in the U.S. and the first new branded product to be introduced in the U.S. for uUTI in more than 25 years – offering a critical option for patients and physicians facing a shrinking arsenal of effective oral therapies.